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Abstract: This paper reviews the current clinical data for the role of transdermal buprenorphine 
(BUP TDS) in the treatment of diverse acute and chronic pain syndromes. Literature searches 
were carried out using PubMed (1988 to June 2009). The published findings seem to support 
hypotheses regarding the rather unique analgesic mechanisms of buprenorphine as compared 
with pure µ-opioids like morphine and fentanyl. However, the exact mechanism of this analgesic 
efficacy still remains largely unknown despite recent advances in preclinical pharmacological 
studies. Such assessments have demonstrated the sustained antihyperalgesic effect of 
buprenorphine in diverse animal pain models. These findings are supported in a growing 
number of clinical studies of oral, intrathecal, intravenous, and BUP TDS. This review paper 
focuses almost entirely on the clinical experience concerning the transdermal administration of 
buprenorphine, although preclinical aspects are also addressed in order to provide a complete 
picture of the unique pharmacological properties of this analgesic drug. Mounting evidence 
indicates the appropriateness of BUP TDS in the treatment of diverse acute and chronic pain 
syndromes which have been less or not responsive to other opioids. Additionally, BUP TDS 
seems to hold great promise for other difficult-to-treat (pain) conditions, such as patients in the 
intensive care setting. However, its use is somewhat tempered by the occurrence of local skin 
reactions which have been shown to be often therapy resistant. Further studies are certainly 
warranted to identify even more precisely the clinical syndromes that are most sensitive to 
buprenorphine treatment, and to compare buprenorphine to other opioids in head-to-head trials 
of acute and chronic pain conditions.
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Introduction
Buprenorphine, a potent centrally acting opioid analgesic, has been used extensively in 
clinical practice, and in wide variety of settings for 30 years.1 Buprenorphine is an opioid 
analgesic with a unique physcio-chemical profile. It is a derivative of the morphine 
alkaloid thebaine. As such, it belongs to the 6, 14-endo-ethanotetrahydroorivavine 
class of compounds that include other potent µ-agonists such as diprenorphine and 
etorphine.2 Buprenorphine is N-dealkylated to norbuprenorphine mainly in the liver 
by CYP3A4 and to a lesser extent by CYP2D6, but also by the gut wall, producing 
the major metabolite norbuprenorphine and several glucuronides of less importance.3 
CYP3A4 inducers, such as ritanovir, amiodarone, ketoconazole, and erythromycin, but 
also grapefuit and star-fruit juice, will thereby elevate the serum buprenorphine level. 
Buprenorphine is eliminated independently of the application route predominantly 
via the gastrointestinal tract (for almost two-thirds), with the feces containing mainly Journal of Pain Research 2009:2 118
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unchanged buprenorphine, and only to a lesser extent via the 
urine (remaining one-third), which contains conjugates of the 
mother compound and norbuprenorphine. Renal impairment 
is thus not expected to cause increased plasma accumulation of 
the mother compound. But renal insufficiency could still lead 
to an increased plasma concentration of norbuprenorphine 
as the majority of this metabolite is excreted via the urine. 
Furthermore, one study showed that hemodialysis did not 
affect buprenorphine plasma levels, leading to stable analge-
sic effects during such therapy.4 This was proven by the fact 
that no differences in pain relief before and after hemodialysis 
could be observed.
Oral administration is a recommended route of delivery 
for opioid analgesics. However, some opioids are not ame-
nable to oral administration because of extensive first-pas 
metabolism and poor oral bioavailability.5 Furthermore, some 
oral opioid analgesics, such as propoxyphene, are available 
only in immediate-release formulations, which require mul-
tiple daily doses to maintain around-the-clock pain control in 
patients suffering from persistent pain. Multiple daily dosing 
can be inconvenient and may decrease compliance, impair 
health-related quality of life, and fail to provide sufficient 
around-the-clock analgesia.6–8 Several delivery formulations 
of buprenorphine have been investigated over the years. The 
older sublingual and intravenous formulations have been sup-
plemented by a new polymer matrix patch system.9 Because 
it is non-invasive, easily administerd, and has a sustained 
effect, the transdermal route is beneficial in selected patients, 
potentially increasing adherence to the analgesic regimen.10,11 
Transdermal delivery systems (TDS) are an effective method 
for drug administration in patients with chronic pain.12 The 
TDS allows passive transdermal diffusion of medication over 
a prolonged period, while maintaining a constant therapeutic 
dose. The physicochemical properties of buprenorphine (low 
molecular weight, high lipophilicity, and high affinity for, 
and slow dissociation from, the µ-opioid receptor) mean 
it is well suited for transdermal delivery. In this way, prob-
lems associated with oral drug formulations, such as poor 
absorption from the gastrointestinal tract, hepatic first-pass 
metabolism, and low and variable bioavailability, may be 
avoided. Thus, transdermal buprenorphine is particularly 
useful for patients who are not able to swallow properly or 
who have gastrointestinal disorders or preexisting nausea and 
vomiting (eg, elderly, patients treated with chemotherapy, 
patients on intensive care units). There are currently three 
transdermal buprenorphine preparations (BUP TDS). First, 
a 3-day patch (Transtec®), releasing at one of three defined 
rates: 35 µg/h, 52.5 µg/h, or 70 µg/h. Dose effectiveness is 
reached within 12 to 24 hours, and is kept at a constant dose 
rate control for 96 hours. In addition, there are low-dose 7-day 
buprenorphine patches (Norspan®) which are available in 
strengths of 5 µg/h, 10 µg/h, or 20 µg/h, respectively. Steady 
state is achieved by day 3 following the first application. After 
removal of the Norspan transdermal patch, approximately 
50% buprenorphine concentration remains after 12 to 
24 hours. In Germany a third transdermal preparation is 
available, containing a combination of buprenorphine and 
aloe vera.
Buprenorphine is a molecule that is particularly suited 
for transdermal delivery because of its high potency, high 
lipophilicity (octanol-to-water partition coefficient of 1217), 
and low molecular weight (467 kDa).13,14 In addition, it is 
able to achieve good permeability through the dermis and 
deep tissue layers. Therapeutic efficacy is achieved with daily 
doses of 0.5 to 2 mg, making it 25 to 50 times more potent 
as an analgesic, per milligram, than morphine. Rather than 
sitting in a reservoir, buprenorphine is incorporated into an 
adhesive polymer matrix, with a distinct backing layer of foil 
that acts as an occluding functioning system.
In recent years, it has become clear that buprenorphine 
cannot be classified as a typical µ-agonist. Although this 
review article emphasizes the critical evaluation of the 
clinical applications of transdermal buprenorphine for-
mulations, it seems essential to start by providing a short 
overview of the most important pharmacological features 
of this unique drug. More comprehensive overviews of 
buprenorphine’s pharmacological profile can be found in 
recent reviews.15–19
Buprenorphine: a unique receptor 
agonist/antagonist
The complex interaction of a particular opioid with 
any of the four different opioid receptor types (µ, κ, 
δ, and σ), found both peripherally and centrally, determines 
the pharmacological effect of an opioid compound. 
As mentioned earlier, buprenorphine is a semi-synthetic 
oripavin-derivative of the morphine alkaloid thebain 
with analgesic potency 25 to 50 times greater than that 
of morphine.20 It binds to µ-, κ-, δ-opioid, and nociceptin 
receptors and has a unique analgesic mechanism of 
action – one quite different from morphine and fentanyl.21 
Buprenorphine’s potent analgesic effect results from its 
partial agonist activity at the µ-opioid receptor, and its high 
affinity for this receptor results in a long duration of action, 
making it a possible candidate for the effective management 
of neuropathic pain.22Journal of Pain Research 2009:2 119
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κ3-opioid receptor antagonist
In addition to being an antagonist at the κ- and δ-opioid 
receptors, buprenorphine has shown some specific interaction 
with the κ3-opioid receptor subtype.23 Evidence linking this 
receptor to neuropathic pain shows that serotonin specific 
re-uptake inhibitors potentiate κ3-receptor-mediated analgesia, 
while having no detectable effect on the µ-receptors.24 
Furthermore, κ-opioid agonists are potent antinociceptive 
agents against formalin-induced pain – both in neonates and 
adults – with no antinociceptive effect in the tail flick test.25
K+-channel openers
G-protein-coupled receptor (ie, µ- and δ-opioid receptor and 
α2−receptor) agonists open specific K+ channels in neurons, 
namely the KATP
26,27 and the G-protein-gated inward rectifier 
potassium (GIRK) channels.28 Both types of K+ channel are 
involved in opioid-induced antinociception and have been 
studied extensively.
The opening of KATP channels seems to play an important 
role in morphine-induced analgesia at supraspinal, spinal, and 
peripheral levels. While buprenorphine has been shown to 
open peripheral KATP channels, it also seems to be sensitive 
to the effects of KATP channel openers and blockers.29 Con-
versely, morphine- and methadone-induced analgesia is only 
modestly enhanced or attenuated by KATP channel openers and 
blockers, respectively, and fentanyl exhibits no interactions 
with KATP agents. This suggests that at least 2 subgroups 
can be distinguished among µ-opioid receptor agonists, 
each inducing antinociception through different effector 
mechanisms. KATP channels represent novel opportunities for 
enhancing opioid analgesia, particularly in pain syndromes 
where expression of these ion channels is altered.30,31
Nociceptin/orphanin FQ(Noc/OFQ) 
receptors
Buprenorphine exhibits a lower (50% to 70%) degree of 
agonism at the nociceptin receptor compared with the endog-
enous ligand nociceptin, which leads to antinociception via 
opioid receptor-like receptor-1 (ORL-1)-mediated mecha-
nisms, particularly at high doses.32–35 Following systemic 
administration of buprenorphine, this analgesic effect can be 
countered by simultaneous activation of supraspinal ORL-1 
receptors.36 Conversely, sole activation of spinal ORL-1 recep-
tors by buprenorphine may lead to an important antinocicep-
tive effect, which might explain the strong analgesic action 
observed after intrathecal administration of buprenorphine;37–40 
however, some evidence suggests a supraspinal site of action 
after neuraxial administration.41,42 Overall, the clinical result 
following administration of buprenorphine, by whichever 
route, is dose-related analgesia and, therefore, the precise 
involvement of the ORL-1 receptor remains unclear.18
Review methodology
A systematic and extensive literature search was carried out 
using the PubMed database (from 1988 to June 2009). The 
search terms included ‘buprenorphine’ and ‘transdermal’, 
as well as ‘nociceptive pain’, ‘neuropathic pain’, ‘acute 
pain’, ‘chronic pain’, ‘hyperalgesia’, and ‘allodynia’. To our 
knowledge this review includes almost all of the available 
information on the subject of transdermal buprenorphine and 
pain. The data consist of double-blind, randomized controlled 
trials (RCTs), open-label studies, retrospective analyses, 
observational studies, two post-marketing surveillance 
(PMS) studies, a number of case studies, as well as some very 
recent high-quality reviews on buprenorphin. Some cases of 
abuse of intravenous buprenorphine, as well as publications 
on sublingual administration of buprenorphine, have been 
excluded as they are irrelevant to the subject of this review. 
The Oxford quality scoring system, better known as the Jadad 
scale, was applied to assess independently the methodologi-
cal quality of the included trials.43 It was however not the 
intention of the authors to create a meta-analysis of all of the 
published studies on BUP TDS.
Transdermal buprenorphine:  
clinical efficacy
Published results from a growing number of clinical studies 
demonstrate the interesting analgesic profile of buprenor-
phine in the treatment of diverse pain conditions, often 
previously unresponsive to opioid therapy. Studies are hereby 
reviewed rather in order of their clinical significance.
Two RCTs have previously assessed the effectiveness 
of BUP TDS for the management of chronic cancer and 
non-cancer pain (see Table 1 for methodological overview 
and quality grading). One of these multicenter RCTs 
demonstrated the potential analgesic efficacy and toler-
ability of BUP TDS in patients with chronic pain.44 In this 
study of 157 patients, BUP TDS (35 and 52.5 µg/h) was 
associated with a significantly higher response rate compared 
with placebo (36.6% [P  0.05] and 47.5% [P  0.005], 
respectively). A notable, but not significant, improvement in 
response (33%) was seen with the 70 µg/h dose. Administra-
tion of BUP TDS significantly reduced (56.7%; P  0.005) 
administration of sublingual buprenorphine rescue analgesia 
compared with placebo. The improvement in quality of sleep, 
in addition to the good tolerability profile and reduced need Journal of Pain Research 2009:2 121
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for rescue analgesia, suggest BUP TDS is beneficial for the 
treatment of diverse chronic pain states. In addition, this study 
indicated no difference in efficacy of BUP TDS between 
neuropathic and non-neuropathic pain conditions.
In the second double-blind RCT, 137 patients were 
randomized to receive BUP TDS patches (72 hours) or 
placebo.45 Rescue therapy in both groups was sublingual 
buprenorphine. Ninety patients received buprenorphine and 
47 were treated with placebo patches. Forty-five patients had 
cancer pain and 92 had non-cancer pain. Patients receiv-
ing BUP TDS significantly reduced their consumption of 
sublingual buprenorphine compared with the control group 
(P = 0.03). Patients’ assessment of pain intensity and relief 
suggested better analgesia with BUP TDS, although these 
results never gained statistical significance during the study 
protocol (P  0.05).
A total of 239 patients from the previously described 
RCTs participated subsequently in an open label follow-up 
study, which demonstrated that BUP TDS was effective in 
controlling chronic pain over a long period, without the 
need of significant dose increases (lack of tolerance devel-
opment).46 The maximum study participation was 3.4 years 
in cancer patients (n = 134), and 5.7 years in non-cancer 
patients (n = 105). In total, 90% of patients reported at least 
satisfactory pain relief, measured using a 4-point verbal 
scale. Moreover, BUP TDS was generally well tolerated 
during long-term treatment both in cancer and non-cancer 
patients, with the most common side effects being nausea 
(9.2%), dizziness (4.6%), vomiting (4.2%), constipation 
(3.8%), and tiredness (2.9%). Local adverse reactions with 
BUP TDS included erythema (12.1%), pruritus (10.5%), 
and exanthema (8.8%). This study provided some highly 
interesting clinical findings, since the results indicate the 
absence of development of tolerance during longer periods 
of treatment. In addition, incidence of side effects remained 
low during the prolonged treatment.
Similar results were observed during a large-scale PMS 
study of 13,179 patients with moderate-to-severe chronic 
cancer (25%) or non-cancer (72%) pain. The effectiveness 
and tolerability of BUP TDS were assessed over an average 
treatment time of 60.8 days.47 The most frequent diagnoses 
in non-cancer patients were musculoskeletal disorders (77%) 
and neuropathy (23%), and the majority of patients were 
treated with BUP TDS 35 µg/h. In total, 80% of patients 
reported good or very good pain relief with BUP TDS at the 
final assessment (median time 63 days), compared with only 
6% at the start of the study. Good or very good pain relief was 
achieved in 84% of cancer patients and 80% of non-cancer 
patients. At the end of the study, only 4% of cancer patients 
and 6% of non-cancer patients reported poor or no pain relief. 
This study also revealed that the overall incidence of both 
systemic and local side effects is lower in clinical practice 
compared with clinical studies. Patients reported vomiting 
(1.6%), nausea (4%), constipation (1%), pruritus (0.7%), 
erythema (0.5%), and contact dermatitis (0.8%). Moreover, 
compared with PMS data of fentanyl transdermal patch 
(FEN TDS), long-term use of BUP TDS resulted in a lower 
incidence of CNS side effects.47,48
A more recent, but somewhat smaller, prospective multi-
center PMS study obtained comparable results.49 This study 
was aimed at obtaining information on the efficacy, toler-
ability and safety of a transdermal buprenorphine patch in 
patients with moderate to severe chronic (cancer and non-
cancer) pain. In addition it was evaluated to what extent a 
two fixed patch change days per week were simplifying the 
therapy. The evaluation included pain intensity, the dosage 
of the applied analgesics and additional therapies, the renal 
function (by serum creatinine) and adverse events. A total 
of 3654 patients were treated for a mean of 50.4 days. Using 
the 11-point Likert-scale the mean pain intensity decreased 
from 6.3 at the time when patients were switched to the BUP 
TDS to 2.6 at the last treatment evaluation. The matrix patch 
was safe and well tolerated also in patients with advanced 
renal insufficiency. Adverse events were reported in 6.7% of 
the patients. Most (89.3%) of the physicians stated a prefer-
ence for transdermal buprenorphine with the two fixed patch 
change days per week compared to the pre-treatment. From 
the physicians’ view the two fixed patch change days per 
week even facilitated the guidance of therapy.
For this application regimen, Likar et al even investigated 
the possibility of a 4-day instead of the usual 3-day regimen.50 
The primary recommendation contained in the prescribing 
information is that transdermal patches be worn for a 3-day 
period before application of a new patch. This single-center, 
randomized, open-label, crossover Phase III study was there-
fore conducted to evaluate the potential for extending the time 
the buprenorphine patch is worn from 3 to 4 days. Patients 
suffering from chronic moderate or severe pain of malignant 
or non-malignant origin were included. Study participants had 
already responded to at least 4 weeks of BUP TDS, and had 
achieved steady-state conditions for at least 2 weeks before 
enrollment. The primary endpoint was patients’ rating of 
the quality of treatment (analgesic efficacy and tolerability, 
rated on a 5-point scale: very good, good, satisfactory, poor, 
and inadequate) at the completion of each treatment regimen 
(12 days each). Also recorded were physicians’ ratings of Journal of Pain Research 2009:2 122
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the quality of treatment; pain intensity, rated on an 11-point 
numerical rating scale (from 0 = no pain to 10 = worst pain 
imaginable) and on the McGill Pain Questionnaire (MPQ) 
(maximum pain = 3.0); health status, assessed using the 
36-item Short-Form Health Survey (SF-36), expressed as 
a percentage of the best health condition (100%); and pain 
relief (5-point scale: complete, good, satisfactory, slight, and 
none). Local skin tolerability was evaluated for objective and 
subjective dermatologic symptoms at the patch application 
sites. Patients recorded daily pain intensities at specified 
times of day and night, pain relief (5-point verbal rating 
scale), and sleep duration (2 hours, 2 to 3 hours,3 to 
6 hours, or 6 hours) in a diary. The safety profile was 
evaluated based on standard monitoring of adverse events, 
vital signs, and routine laboratory tests. Forty-nine white 
patients (25 women, 24 men) were enrolled; their mean 
(SD) age was 61.6 (11.5) years, and their mean weight 
was 74.7 (16.7) kg. The most common source of pain was 
musculoskeletal disorders (40 patients), followed by nervous 
system disorders (10), neoplasms (9), injuries (5), and other 
causes (6). Forty-one patients completed the study; 2 patients 
discontinued because of adverse events, 1 because of lack of 
efficacy, and 5 for non-medical reasons. Thirty-three patients 
provided data per protocol. Patients in the perprotocol popula-
tion received a mean (SD) transdermal buprenorphine dose of 
49.9 (38.9) µg/h. The proportion of patients in the per-protocol 
population rating the quality of treatment as adequate (com-
bined ratings of very good, good, and satisfactory) was 93.9% 
(31/33) for both regimens. The physicians' ratings indicated 
adequate quality of treatment in 93.8% (30/32) of patients 
applying 4 patches for 3 days each and 97.0% (32/33) of 
patients applying 3 patches for 4 days each. Mean (SD) pain 
intensity scores on the numerical rating scale were similar after 
completion of the 3- and 4-day regimens (3.73 [1.88] and 3.88 
[1.75] points, respectively), as were MPQ scores (0.79 [0.67] 
and 0.79 [0.78]). The mean (SD) proportion of days with at 
least satisfactory pain relief was 83.9% (26.1%) and 85.6% 
(24.4%) for the 3- and 4-day regimens; the corresponding 
proportions of nights with at least satisfactory pain relief were 
85.2% (26.6%) and 88.1% (21.4%). Continuously assessed 
pain intensities at specified times of day and night (numerical 
rating scale) did not differ significantly between regimens. 
Mean SF-36 health status scores did not differ significantly 
between regimens (total score: 37.7% [17.0%] and 37.7% 
[17.3%]). Mean rates of nights with good sleep quality were 
28.5% (39.9%) for the 3-day regimen and 36.0% (42.6%) for 
the 4-day regimen. Local skin tolerability was comparable for 
the 3- and 4-day regimens, with objective findings (mainly 
erythema) at the patch-application sites in 17 of 32 and 
11 of 33 patients, respectively, and subjective symptoms 
(mainly itching) in 16 of 32 and 13 of 33 patients. The most 
common adverse events in the safety population were nausea, 
dizziness/giddiness, and malaise/fatigue (3/49 [6.1%] each). 
On the basis of the above-mentioned results49,50 we currently 
recommend our patients to apply the buprenorphine patches 
during 3.5 days, resulting in 2 fixed patch change days per 
week (eg, on Monday morning and Thursday evening).
Spanish pain centers recently completed a retrospective 
multicenter safety and efficacy study, assessing the 
effectiveness of BUP TDS in a large number of patients 
(n = 1465) suffering from moderate to severe pain.51 Pain could 
have any etiology. All patients suffered from pain 50 mm 
on a 0 to 100 mm visual analog scale (VAS) and were 
switched to BUP TDS receiving a dose of 52.5 µg/h for 
at least 14 days during the previous months. An absolute 
reduction of 25.1 points in VAS score was observed over a 
median period of 3.7 months. In addition, the VAS score was 
reduced by at least 10% in 88.4% of the patients. Incidence 
of episodic pain also decreased significantly. Most (82.5%) 
patients rated this treatment as “good” or “very good”. Of 
all patients, 50.2% experienced an adverse event, which in 
48.8% was drug-related, and considered serious in 4.0%.
Table 2 Studies on the efficacy of trandsermal buprenorphine (BUP TDS) in neuropathic pain
Study Design/methods Condition(s) Intervention/control/ 
length of treatment
Outcome  
measures
Results Quality 
grade
Rodriguez-Lopez52 Retrospective study 
(n = 237)
Non-malignant 
neuropathic pain
Efficacy and tolerability 
of BUP TDS 35 and 52.5 µg/h 
Treatment period of 8 weeks
vAS score 
Sleep score
55% reduction in vAS 
score 
Significant improvement 
in sleep score
1
Penza et al53 Open-label study 
(n = 30)
Chronic painful 
neuropathy 
(5 on vAS)
Efficacy and tolerability of 
increasing doses of BUP TDS 
Treatment period of 42 days
Number of patients 
achieving at least 
30% pain reduction 
at day 42
13/30 achieved 30% 
reduction 
9/30 drop-outs, and 8/30 
failed to reach outcome
1
Abbreviation: vAS, visual analogue scale.Journal of Pain Research 2009:2 123
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While the aforementioned studies assessed the efficacy of 
buprenorphine in a heterogenous group of pain conditions, 
additional studies and reports specifically focused on painful 
neuropathic syndromes (see Table 2 for an overview of these 
studies and quality grading). A retrospective study across 
20 pain management centers assessed the effectiveness of 
BUP TDS (35 and 52.5 µg/h), over an 8-week period, in a total 
of 237 patients suffering from non-malignant neuropathic 
pain.52 Tramadol (75 to 110 mg/day) was provided for the 
treatment of breakthrough pain. Significant improvements 
in VAS scores (P  0.001) were achieved at all endpoints 
compared with baseline, a 55% reduction in mean VAS 
pain scores being achieved by week 8. Improvements were 
most notable in those symptoms rated ‘severe’ at baseline. 
Significant improvements (P  0.001) in sleep scores pro-
vided additional support for the clinical effectiveness of BUP 
TDS, with increases from 4.9 (±1.5) hours to 6.2 (±1.39) 
hours. Finally, it was shown that buprenorphine TDS had 
a good safety and high user compliance profile, which 
improved even further over the course of the treatment.
A very recent open-label study investigated the efficacy, 
safety, and tolerability of BUP TDS in 30 patients suffering from 
moderate to severe chronic painful neuropathies (VAS  5).53 
Starting doses of 35 µg/h were increased in case of unsat-
isfactory pain control. Primary endpoint was the number of 
patients achieving at least 30% pain relief at day 42 (in order 
to evaluate short- and intermediate-term efficacy). Finally, 
13 patients achieved this endpoint. Nine patients dropped out 
for side effects, and 8 patients did not meet the primary out-
come. These results seem to indicate that BUP TDS induces 
clinically meaningful pain relief in about 40% of the patients 
suffering from chronic painful neuropathies.
Although of much more limited scientific value, patient 
case reports often provide a valuable insight into pain 
management in daily clinical practice. The efficacy of BUP 
TDS in the treatment of nerve-injury-induced pain is further 
demonstrated in case reports presented by Likar and Sittl.54 
Two patients with neuropathic pain, and two patients with 
nociceptive pain with a neuropathic component, experienced 
well-tolerated and prolonged pain relief, and fewer episodes 
of breakthrough pain with BUP TDS compared with FEN 
TDS. The patients switched from other opioids to buprenor-
phine without adverse effects and required a lower level of 
buprenorphine to match the level of analgesia achieved with 
previous opioids (70%).
Other studies have been focusing on the treatment of 
cancer pain (see Table 3 for an overview of these studies and 
quality grading). A company-sponsored study has investigated 
the efficacy and safety of BUP TDS in patients suffering 
from severe cancer pain.55 Two hundred eighty-nine cancer 
patients were included in a randomized, placebo-controlled, 
study with an enriched design, making this study the largest 
placebo-controlled study ever performed in patients with 
cancer. Treatment with BUP TDS 70 µg/h was compared to 
placebo in opioid-tolerant cancer patients requiring strong 
opioid in a dose range of 90 to 150 mg/d oral morphine 
equivalents. All patients first entered a run-in phase during 
which they were converted to BUP TDS. Those patients who 
could be stabilized on BUP TDS were then randomized to 
transdermal buprenorphine patches or placebo patches for a 
2-week maintenance phase. Hundred patients discontinued 
treatment during the run-in phase due to lack of efficacy 
or adverse events, while 189 patients continued treatment 
in the maintenance phase (94 BUP TDS vs 95 placebo). 
Of these, 31 discontinued treatment, a vast majority of whom 
came from the placebo treatment group (24 vs 7 BUP TDS). 
A significantly higher number of patients responded well to 
the treatment in the buprenorphine group versus the placebo 
group (74.5% vs 50%, P = 0.0003). These responder results 
were further supported by lower daily pain intensities, lower 
intake of rescue medication (buprenorphine sublingual tablets) 
and lower dropout rates in the BUP TDS group. It should be 
noted that even during the run-in period, the mean daily pain 
intensity and the mean daily intake of rescue medication 
both decreased in 70% of patients during the first 12 hours 
following active patch application, indicating a rapidly devel-
oping distinct analgesic response from BUP TDS.
An open PMS study conducted in Spain enrolled 
1223 patients (male and female, mean age 64.6 years), 
207 (18%) of whom had recorded chronic moderate-to-severe 
cancer pain that had not responded to non-opioid analgesics.56 
BUP TDS 35 µg/h was used to treat the majority of patients 
(89%). After 3 months, the 35 µg/h patch was still being 
used by 52% of patients, and they were satisfied with the 
pain relief provided. Pain relief was reported as very good 
or good in 89% of patients, increasing from 5% prior to the 
start of the study. Another open, multicenter, retrospective, 
pharmacoepidemiological study was performed by the same 
principal author and used data collected from 164 patients 
(average age 64.3 ± 12 years) with moderate-to-severe 
cancer pain attending pain centers throughout Spain.57 
The majority of patients continued with low doses of BUP 
TDS (35 or 52.5 µg/h) until the end of the study. At baseline 
84% of patients reported a pain score of 7. After 2 weeks, 
41% of patients reported a pain score of 4, rising to 76% 
after 8 weeks.Journal of Pain Research 2009:2 124
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Lately, the first reports have been emerging on 
the effective use of BUP TDS in young children (aged 
3 to 5 years) suffering from cancer pain.58 In all cases distinct 
decreases in pain scores were observed, with reduction of 
the overall amount of medications (especially opioids) and 
improvement of uninterrupted sleep. Although only limited 
data are available on the use of BUP TDS in children, these 
cases indicate that BUP TDS could allow good analgesia 
without significant side effects in children suffering from 
severe cancer-related pain.
Recently the findings of an expert panel consensus 
were published on the role of BUP TDS in the treatment 
of cancer pain.59 The consensus was that BUP TDS has a 
valuable role to play in the treatment of chronic cancer pain 
because of its efficacy and good safety and tolerability pro-
file, including a low risk of respiratory depression, a lack of 
immunosuppression, and a lack of accumulation in patients 
with impaired renal function. The registered dose range of 
35 to 140 µg/h was considered adequate to achieve sufficient 
pain relief in most patients, although some members of the 
panel presented data showing that increases beyond this 
dose range provided improved pain relief if slow titration 
is used. However, it was generally felt that more evidence 
was needed before this could become generally acceptable. 
Nevertheless, a number of general recommendations were 
made. Large-scale, randomized clinical studies are needed 
to provide product comparisons on the use of analgesics in 
the treatment of neuropathic pain, although it was recognized 
that such studies may not be practicable. Physicians should 
be made more aware of the problem of hyperalgesic effects 
of some opioids in long term use. Buprenorphine in contrast 
has been described to exert an antihyperalgesic effect.60 The 
development of analgesic tolerance with some opioids in 
long-term use and the lack of it with buprenorphine requires 
further studies.
Finally, in contrast to older beliefs that the use of 
buprenorphine would prevent future use of opioids (due to 
an irreversible and permanent blocking of opioid receptors), 
it has been shown that use of BUP TDS in cancer patients 
does not impede them from future opioid therapies.61 The aim 
of this study was to confirm that the concomitant presence of 
FEN TDS and BUP TDS may be feasible without important 
consequences, using doses presumed to be equianalgesic. 
A prospective “N of 1” study was carried out in a sample of 
volunteers with cancer pain receiving stable doses of FEN 
TDS or BUP TDS, with adequate pain and symptom control. 
In the study design, each patient provided data before and 
after a switch from one opioid to the other and then back 
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to the previous one. Sixteen patients receiving daily stable 
doses of 0.6 or 1.2 mg of FEN TDS were switched to BUP 
TDS using an FEN-BUP ratio of 0.6 to 0.8. After 3 days, 
the buprenorphine patch was removed and a fentanyl 
patch was placed for another 3 days. Six patients receiving 
buprenorphine were switched to FEN TDS and then rotated 
back to BUP TDS with the same dosing considerations. 
No statistical differences in changes in pain and symptom 
intensity during switching and between the two different 
sequences were observed. No significant changes in rescue 
doses of oral morphine were reported at the same intervals. 
These results clearly indicate that cancer patients receiving 
stable doses of transdermal fentanyl or buprenorphine can 
be safely switched to an alternative transdermal opioid. Safe 
and efficacious opioid rotation from high-dose morphine 
to BUP TDS has also been demonstrated in different types 
(musculo-skeletal, cancer, and neuropathic) of severe chronic 
pain.62 A final study assessed the efficacy and tolerability of 
an alternative transdermally applied opioid (either fentanyl 
or buprenorphine) in 32 patients with chronic cancer pain 
receiving insufficient analgesia using their present treat-
ment.63 Sixteen were switched from FEN TDS to BUP TDS 
(75 µg/h fentanyl converted to 52.5 µg/h buprenorphine), 
and 16 from BUP TDS to FEN TDS (70 µg/h buprenro-
phine converted to 25 µg/h of fentanyl). The dosage used 
was 50% of that indicated in equipotency tables. Pain relief 
was assessed at weekly intervals for the next 3 weeks. There 
was no significant difference in either pain relief or rescue 
medication use between the two patient groups. The number 
of patients with adverse events decreased during the study. 
These results clearly indicate that opioid switching at 50% 
of the calculated equianalgesic dose significantly reduces 
pain levels and rescue medication.
Other studies have been examining the efficacy of BUP 
TDS in different types of chronic, non-cancer, pain. One 
recent randomized study investigated the efficacy of BUP 
TDS as add-on therapy in the treatment of ischemic pain.64 
This is an interesting protocol from a clinical standpoint since 
ischemic pain is generally considered as difficult to treat and 
often unresponsive to (strong) analgesics. Eighty-six patients 
were randomized in 2 groups. In the first group, a 35µg/h 
BUP TDS was applied and an additional peridural infusion 
of ropivacaine/morphine (200 mg + 2 mg) was established. 
In the second group, an identical ropivacaine and morphine 
epidural analgesia was obtained but a placebo patch was 
added on top. VAS for pain was used as the primary efficacy 
parameter. In addition, short-form MPQ scores and a score 
for pain interference with sleep were obtained from the 
patients every week for a period of 4 weeks. The subjects in 
the BUP TDS group reported a significant reduction in pain, 
increased sleep, and even a lower incidence of side effects 
compared with the control group (all P  0.05).
The efficacy and safety of the 7-day low-dose 
buprenorphine matrix patch was recently evaluated in 
routine clinical practice in a multicenter observational 
study in 4263 patients with chronic osteoarthritis pain.65 
During treatment a significant decrease in mean pain could 
be observed (6.9 before treatment to 2.9 on a 11-point scale 
at the end of the observation period). Furthermore, the 
investigators observed a decrease in additional analgesic 
medication and improvements in mobility and quality of 
sleep. Only 4.5% of the patients displayed adverse effects, 
making BUP TDS a safe way of chronic pain relief for 
osteoarthritis patients.
In a similar patient population (chronic osteoarthritis 
pain of the hip and knee) the efficacy and safety of low dose 
(5, 10, and 20 µg/h) BUP TDS was compared to prolonged-
release tramadol tablets.66 Eligible patients were adults 
with a clinical and radiologic diagnosis of osteoarthritis 
(OA) and moderate to severe pain, while using paracetamol 
4000 mg/d for pain during the screening week. Patients 
were randomized in a 1:1 ratio to receive either low-dose 
7-day buprenorphine patches (patch strengths of 5, 10, and 
20 µg/h, with a maximum dosage of 20 µg/h) or twice-daily 
prolonged-release tramadol tablets (tablet strengths of 75, 
100, 150, and 200 mg, with a maximum dosage of 400 mg/d) 
over a 12-week open-label treatment period. Supplementary 
paracetamol was available as rescue medication throughout 
the study. The primary endpoint was the difference in 
BS-11 scores from baseline to the completion of treatment 
(non-inferiority was assumed if the treatment difference 
on the BS-11 scale was –1.5 boxes). Secondary efficacy 
variables were rescue medication use, sleep disturbance 
and quality of sleep, and patients' and investigators' global 
assessments of pain relief. One hundred thirty-four patients 
(69 receiving 7-day buprenorphine patches and 65 receiving 
tramadol tablets) were randomized and received 1 dose 
of study medication. Of the 2 treatment groups 98.6% and 
100% were white, respectively, with mean (SD) ages of 64.4 
(11.1) and 64.2 (9.3) years. Both treatments were associated 
with a clinically meaningful reduction in pain from base-
line to study completion. The least squares mean change 
from baseline in BS-11 scores in the 7-day buprenorphine 
patch and tramadol tablet groups were –2.26 (95% CI, –2.76 
to –1.76) and –2.09 (95% CI, –2.61 to –1.58). The efficacy 
of 7-day buprenorphine patches was non-inferior to that Journal of Pain Research 2009:2 127
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of prolonged-release tramadol tablets. The incidence of 
adverse events (AEs) was comparable in the 2 treatment 
groups: 226 AEs were reported in 61 patients (88.4%) in 
the 7-day buprenorphine patch group, and 152 AEs were 
reported in 51 patients (78.5%) in the tramadol group. The 
most common AEs in the 7-day buprenorphine patch group 
were nausea (30.4%), constipation (18.8%), and dizziness 
(15.9%); the most common AEs in the tramadol tablet group 
were nausea (24.6%), and fatigue (18.5%). Most patients 
(47/67 [70.1%] in the 7-day buprenorphine patch group 
and 43/61 [70.5%] in the tramadol tablet group) reported 
that they would prefer a 7-day patch to a twice-daily tablet 
for future pain treatment. It can therefore be concluded that 
in patients with chronic, moderate to severe OA pain of the 
hip and/or knee, 7-day low-dose buprenorphine patches is an 
effective and well-tolerated analgesic which is non-inferior 
to prolonged-release tramadol tablets.
Another multicenter, double-blind, parallel-group study 
compared the efficacy of buprenorphine transdermal 7-day 
patches and placebo in subjects with persistent non-cancer 
pain who required opioid analgesics.67 Adult subjects (588) 
with at least a 2-month history of non-cancer-related pain 
for which they received oral opioid combination agents 
entered the open-label run-in phase. Subsequently 267 
were randomized to the double-blind treatment (129 BUP 
TDS, 138 placebo). The primary efficacy variable was the 
proportion of subjects with ineffective treatment during 
the double-blind evaluation phase. The secondary efficacy 
variables were the time to ineffective treatment or patients 
who discontinued for reasons other than ineffective treatment 
and use of escape medication. The results clearly indicated 
that the odds of ineffective treatment were 1.79 times greater 
for placebo than for BUP TDS (P = 0.022). Other indicators 
of effective treatment, such as discontinuation for reason of 
ineffective therapy, showed also significantly higher results 
in the buprenorphine treated patient population. The mean 
amount of escape medication was significantly lower in the 
BUP TDS group than in the placebo group (1.7 vs 2.2 acet-
aminophen tables per day, P = 0.015). A limitation of this 
study is that it did not incorporate direct validated measures 
of pain control, such as the VAS.
An interesting study compared the analgesic efficacy 
and tolerability of BUP TDS in patients over and under 
65 years of age.68 A group of elderly were hereby com-
pared to 2 younger equally sized populations, all requiring 
analgesic treatment for moderate to severe chronic pain of 
diverse etiology. During the 28-day treatment period poten-
tial differences in responsiveness (pain intensity, rescue 
medication, and sleep duration) were observed. Two-thirds 
of the patients completed the study, with similar rates and 
reasons for premature study termination in all age-groups. 
Pain intensities significantly decreased from pretreatment 
until the end of the study without differences between 
age-groups. At the end of the study period daily mean pain 
intensities were even significantly lower in elderly patients 
as compared with both younger age-groups. In addition, need 
for rescue medication was the lowest in elderly patients. Most 
prominent side effects were dizziness, nausea, and local 
skin tolerability issues, with comparable percentages in all 
groups. This study clearly indicated that BUP TDS treatment 
in elderly patients above the age of 65 years is at least as 
effective, tolerable, and safe as in younger patients. With the 
increasing age of patients suffering from pain, the results of 
this study will undoubtly have an important clinical impact in 
the future. In fact, this good tolerability of BUP TDS in the 
elderly has recently been confirmed by a consensus statement 
report.69 Its advantages in the elderly have also thoroughly 
been described in a recent review paper.70
equi-analgesic ratio between 
buprenorphine and other opioids
A clinically very relevant, yet difficult to answer question, 
concerns the equianalgesic ratio of BUP TDS compared 
to other opioids like oral morphine, oral oxycodone, 
and FEN TDS. The equipotency ratio of FEN TDS to oral 
morphine has been established as 1:100; for BUP TDS, 
a ratio of 1:75 has been proposed, although this ratio has 
never been confirmed in clinical studies. Growing evi-
dence from clinical practice, in which much lower doses 
of buprenorphine are used, suggests that this conversion 
ratio may be too high. For a long period BUP TDS was not 
even included in most of the published conversion tables. 
However, a recent study shed some interesting new light 
on this discussion, investigating the equianalgesic ratio in 
a population of cancer patients.71 A sample of consecutive 
patients (n = 11) receiving stable doses of 120 to 140 mg 
of oral morphine or 50 to 100 µg of FEN TDS and who 
reported adequate pain and symptom control, were included 
in this protocol. The authors identified a ratio of 70:1 for oral 
morphine and 0.6:0.8 for FEN TDS. No significant changes 
in pain and symptom intensity were found, except significant 
improvement in reported constipation (P = 0.014). Global 
satisfaction with the analgesic treatment also increased sig-
nificantly after conversion. Similar findings were obtained 
in the previously mentioned study by Aurilio et al, in which 
switching between FEN TDS and BUP TDS at 50% of the Journal of Pain Research 2009:2 128
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calculated equianalgesic dose was shown to significantly 
reduce pain and need for rescue medication.63
Additional interesting information was obtained from a 
study by Wirz et al.72 Although the purpose of this trial was 
to evaluate the effect of long-term treatment with different 
opioid formulations on nausea, emesis, and constipation, 
the authors also evaluated the morphine equivalent opioid 
doses. These morphine-equivalent opioid doses differed 
significantly (mg/d FEN TDS: 183; BUP TDS: 89; oral 
hydromorphone: 143; P = 0.001), because of obvious 
tolerance varying after long-term treatment. The authors 
concluded that conversion ratios for transdermal fentanyl, 
transdermal buprenorphine, and oral hydromorphone did 
not accord with those previously published, because of 
differing occurrences of opioid tolerance after long-term 
therapy.
A third study did also focus on the equipotent doses 
between FEN TDS and BUP TDS.73 The aim of this retro-
spective study was to compare calculated equipotent oral 
morphine doses of FEN TDS with equipotent oral morphine 
doses of BUP TDS prescribed in clinical practice. Patients 
with cancer and non-cancer pain who had received 1 
prescription for FEN TDS or BUP TDS (the all-patients 
groups) were identified from the German IMS Disease 
Analyzer-mediplus database, which contains all relevant data 
on drug prescriptions from 400 practices in Germany. Also 
identified were subgroups of the all-patients groups who had 
received long-term treatment with FEN TDS or BUP TDS 
and were considered to have similar pain intensity, as they 
had previously received similar analgesic medication (the 
identical-cohort groups). Mean prescribed daily doses for the 
all-patients and identical-cohort groups were calculated based 
on the distribution of prescribed patch strengths. Because 
patients could have applied 1 patch, mean prescribed 
daily doses were also calculated based on an assumption 
of double application when appropriate. Equipotent oral 
morphine doses were estimated using equipotency ratios of 
1:100 for FEN TDS and 1:75 for BUP TDS. The all-patients 
groups consisted of 2198 patients with non-cancer pain 
and 2544 patients with cancer pain; the identical-cohort 
groups consisted of 380 patients with non-cancer pain 
and 496 patients with cancer pain (529 women, 347 men; 
mean age, 74 years [range, 25 to 101 years]). Equipotent 
doses of oral morphine were significantly lower in patients 
receiving BUP TDS compared with those receiving FEN 
TDS (P  0.001). In cancer patients, the equipotent oral 
morphine doses of FEN TDS and BUP TDS were 130.9 to 
138.9 mg and 85.2 to 88.8 mg, respectively; in non-cancer 
patients, the corresponding values were 117.0 to 118.3 mg 
and 80.2 to 80.9 mg. Based on these results, an equipotency 
ratio of 1:110 to 1:115 for BUP TDS would appear to be more 
appropriate than the proposed ratio of 1:75. The fact that this 
retrospective analysis conducted in identical cohorts showed 
lower calculated equipotent oral morphine doses in the BUP 
TDS groups compared with the FEN TDS groups calls into 
question the proposed 1:75 ratio for conversion of BUP TDS 
to equipotent oral morphine doses. Based on the findings of 
the described study, an equipotency ratio of 1:110 to 1:115 
may be more appropriate. However, confirmative data from 
larger (prospective and randomized) trials are needed. The 
findings of all the previously described studies clearly indi-
cate that the analgesic drug (in this case buprenorphine), its 
formulation, individual response, and the route of admin-
istrations are all variables of fundamental importance in 
the therapeutic result, and the response to opioids probably 
does not depend on the pathophysiology of the pain alone, 
but rather a complex phenomenon linked to individual fac-
tors. Additional data on equipotency between BUP TDS 
and other opioids have also been indirectly investigated 
in studies on the tolerance development. These studies are 
detailed below.
Transdermal buprenorphine: 
analgesic tolerance
Analgesic tolerance is an important factor to consider when 
choosing the most effective treatment for the management 
of chronic pain. The risk of dose escalation is higher with 
full-opioid agonists such as fentanyl because when they 
bind to µ-opioid receptors downregulation of these receptors 
results from the cell surface. Downregulation of opioid 
receptors does not seem to occur during buprenorphine 
treatment.20
A retrospective data analysis reveals BUP TDS maintains 
effective pain control in patients with cancer (n = 446) and 
non-cancer pain (n = 448), for at least 3 months, without 
the need to increase dose significantly.73 Significantly higher 
increases in mean doses of FEN TDS (P  0.05) were 
documented compared with BUP TDS, which suggests a 
higher risk of analgesic tolerance development with fentanyl 
compared with buprenorphine. These results are supported 
by a more recent study by Sittl et al.74 This retrospective 
analysis used data from the IMS Disease Analyzer-Mediplus 
database, which contains patient-related data documented by 
400 medical practices in Germany. Data from patients with 
non-cancer pain (n = 631) or cancer pain (n = 605) with BUP 
TDS or FEN TDS for at least 3 months were analyzed. Results Journal of Pain Research 2009:2 129
Transdermal buprenorphine in pain management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
showed a significantly greater dose stability (P  0.05) in 
patients, with cancer and non-cancer pain, taking BUP TDS 
compared with FEN TDS.74 A significantly larger propor-
tion of patients receiving BUP TDS had stable dosages 
over the entire treatment period compared with patients 
receiving FEN TDS (non-cancer groups: 56.9% vs 41.6%; 
cancer groups: 50.0% vs 26.2%; both P  0.05). It should 
be noted, however, that the results of this study should be 
analyzed with great care. Indeed, data of this database were 
primarily reflecting the prescription practice of GPs rather 
than a clinical phenomenon. Therefore this study provides 
only circumstantial evidence of the development of analgesic 
tolerance.
Transdermal buprenorphine: clinical 
safety and cost-effectiveness
The safety of buprenorphine has been documented in 
numerous clinical studies, with the incidence of adverse 
effects, typical of this drug class, being lower than other 
opioids used in an identical clinical setting.75 This is possibly 
due to buprenorphine’s ‘bell-shaped’ dose–response curve 
being applicable to the spectrum of adverse events.14 The 
majority of systemic effects occur in the central nervous 
system and gastrointestinal tract and include nausea, 
dizziness, and constipation. Randomized trials have shown 
that local adverse events, resulting from BUP TDS, occur in 
25% of patients in routine clinical practice.9 The relatively 
slow receptor dissociation of buprenorphine may cause fewer 
symptoms of opioid withdrawal than morphine following 
cessation of therapy2 and there appears to be a ceiling to 
its effects on respiratory function.75,76 In a recent study by 
Dahan et al76 the dose–response relationship of intravenous 
buprenorphine (dose range 0 to 0.6 mg) was determined in 
healthy volunteers, and compared to a full µ-opioid recep-
tor agonist with high intrinsic activity, fentanyl (dose range 
0 to 0.5 mg). First, fentanyl, but not buprenorphine, caused 
immediate respiratory arrest upon infusion at doses greater 
than 0.3 mg, lasting 3 to 8 minutes. Second, when plotting 
the dose against the time-effect data (expressed as area-
under-the-curve, a measure of the overall respiratory effect 
of the drug) a linear relationship was shown for fentanyl, 
but non-linear for buprenorphine with a ceiling at doses 
of 0.2 mg and greater. These distinctive pharmacodynamic 
respiratory effects of buprenorphine – lack of apnea after 
even high doses and the development of ceiling effect on 
respiratory function – have evident clinical advantages over 
other opioids such as fentanyl and morphine, contributing 
to the concept that buprenorphine is exceptionally safe to 
use. Moreover, data indicate that ceiling of respiratory effect 
occurs at a much lower dose (0.1 mg/kg) than the ceiling 
in analgesic effect (1.0 to 3.0 mg/kg), which indicates the 
relative safety of buprenorphine combined with its ability 
to produce effective analgesia.75,76 Finally, in the unlikely 
event of buprenorphine-induced respiratory depression, the 
effect can be fully reversed with continuous administration 
of naloxone77 as well as doxapam.78
Recently several studies have reviewed or investigated 
the safety profile of BUP TDS in specific patient populations 
which are especially vulnerable to drug-induced side effects. 
As such, a prospective, open-labeled, controlled trial com-
pared the gastrointestinal symptoms of oral sustained-release 
hydromorphone, FEN TDS and BUP TDS in patients with 
cancer pain.79 Mobility, pain and gastrointestinal symptoms 
were assessed directly and per selected item on the Eastern 
Cancer Oncolgy Group (ECOG) and European Organisation 
for Research and Treatment of Cancer (EORTC) question-
naires, as well as the numeric rating scale (NRS). Only 15% 
of patients suffered from constipation. The incidence of stool 
free periods for more than 72 h was significantly higher with 
transdermal opioids (FEN TDS: 22% and BUP TDS: 21%) 
than with oral hydromorphone (2%). Nausea, consumption 
of emetics and laxatives did not differ significantly between 
the 3 treatment groups. However, score for emesis was sig-
nificantly higher for oral hydromorphone compared to the 
transdermal opioids.
Furthermore, it should be noted that the previously 
mentioned large-scale study in cancer patients,55 showed 
a reduced incidence of adverse events in the maintenance 
phase compared to the run-in period. Indeed, transdermal 
formulations are expected to reduce adverse events by slowly 
releasing the drug into the bloodstream and maintaining a 
steady plasma concentration. Reduced side effects, especially 
for constipation, were repeatedly reported for transdermal 
systems and may be related to a bypass of enteral opioid 
receptors.80 The constipation rate in this study was 7.4%, 
which was comparable to previous results with BUP TDS 
and lower than FEN TDS or sustained-release morphine 
(producing rates between 20% and 44.5%).
Tassinari et al reviewed the adverse effects of trans-
dermal opioids to long-acting morphine in the treatment of 
moderate to severe cancer pain.81 They identified 4 trials, 
comparing the safety of FEN TDS and BUP TDS and 
slow-release oral morphine in 425 patients. A significant 
difference in favor of transdermal opiates was observed 
for constipation, and patients’ preference. No significant 
differences were observed for overall adverse effects, Journal of Pain Research 2009:2 130
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overall gastrointestinal adverse effects, overall neurologic 
adverse effects, nausea, somnolence, hypoventilation, trial 
withdrawal, and changes in opioid treatments. Another 
prospective trial focused on the gastrointestinal symptoms 
occurring under opioid therapy.72 The purpose of this trial 
was to evaluate the effect of long-term treatment with oral 
sustained-release hydromorphone, FEN TDS, and BUP TDS 
on nausea, emesis, and constipation. Randomly selected 
outpatients with cancer pain receiving one of the study 
medications were enrolled in a prospective, open-labeled, 
controlled trial (n = 174). Mobility, pain, and gastrointestinal 
symptoms were assessed directly and per selected item on 
the ECOG and EORTC questionnaires and the NRS, and 
analyzed statistically. Overall, only 15% of patients suffered 
from constipation. 59% took the prescribed laxatives. The 
incidence of stool free periods 72 hours was significantly 
higher with transdermal opioids (FEN TDS: 22%; BUP 
TDS: 21%; oral hydromorphone: 2%; P = 0.003). 21% of 
patients revealed nausea and emesis. The mean NRS for 
nausea (FEN TDS:1.3; BUP TDS: 1.2; oral hydromor-
phone: 1.5; P = 0.6), the consumption of antiemetics (FEN 
TDS: 42%; BUP TDS: 33%; oral hydromorphone: 36%; 
P = 0.6) and laxatives (FEN TDS: 53%; BUP TDS: 66%; 
oral hydromorphone: 61%; P = 0.2) did not differ signifi-
cantly, in contrast to the score for emesis (FEN TDS: 16%; 
BUP TDS: 13%; oral hydromorphone: 33%; P = 0.02). 
The authors conclude that gastrointestinal symptoms of 
cancer-pain patients undergoing an opioid therapy are 
related to multifactorial causes. Transdermal opioids thereby 
showed no benefit over oral controlled-release hydromor-
phone for gastrointestinal symptoms.
Finally, the authors of recent publications on the 
management of chronic pain in the elderly also concluded 
that BUP TDS can be used in clinical practice safely and 
efficaciously for treating chronic pain in elderly.68 Despite 
the very limited available evidence from preclinical and 
clinical work buprenorphine treatment can, because of its 
minor immunosuppressive effects, be recommended for use 
in elderly patients.69
Opioids are known to greatly affect the central nervous 
system. These side effects, such as dizziness and confusion, 
have been shown to lead to an increased risk of falling, 
with subsequent fractures and sometimes long-lasting 
disability. In Germany, a Markov health economic model 
was developed to investigate the cost-effectiveness of the 
most commonly used strong opioids, hereby focusing on 
opioid-related fractures. The most frequently prescribed 
strength/package-size combinations of these opioids were 
taken into consideration. The results of this analysis predict 
that BUP TDS is dominant compared to FEN TDS fentanyl 
and oxycodone by showing better life years gained/quality 
adjusted life-years (QALY).82 As such, BUP TDS represents 
a cost-effective treatment option vs morphine in patients 
with chronic pain. A highly interesting, study assessed 
the cognitive and psychomotor performance under long-
term treatment with BUP TDS in 30 non-cancer patients.83 
A computerized test battery developed to assess driving 
ability was used. Attention reaction, visual orientation, motor 
coordination, and vigilance were evaluated. According to 
tests that predict driving ability, patients receiving BUP 
TDS were shown to be non-inferior to the control group. 
Due to the individual variability of test results, an individual 
assessment is always recommended.
Effective pain management depends upon balanc-
ing the effectiveness of a drug with its side effects. The 
specific pain management needs of patients varies and is 
therefore flexible, yet careful dose titration is the best way 
to achieve balanced pain management. When low-dose 
patches are not available, cutting BUP TDS patches may 
offer a practical solution to gradual dose titration and 
finding the optimal dose for the individual patient. Louis 
reports 5 case studies in which 3 patients had mixed pain, 
including neuropathic pain.84 Two patients used one half 
of a 35 µg/h buprenorphine patch and 1 used one-quarter 
of a 35 µg/h buprenorphine patch, titrated to one 70 µg/h 
BUP TDS patch at 3 months. Cutting the patches in half did 
not seem to affect the efficacy of the analgesic treatment 
in these patients.
Finally, one of the most particular and common adverse 
events with BUP TDS are site-specific adverse effects. 
These include erythematous regions around the patch 
site (approximately 20% incidence) and pruritus at the 
patch application site. Of the latter one of the previously 
described studies reported an incidence of 9.3% vs 5.1% 
after application of placebo patches.67 A double series of 
case reports described the problem of allergic contact derma-
titis to BUP TDS.85,86 Patients developed persistent, pruritic 
erythematous plaques at the contact sites, with sometimes 
even generalized skin eruption.86 Most of these patients 
also reacted to transdermal buprenorphine (without the 
transdermal delivery system), the placebo being negative. 
This skin irritance seems to be perhaps the most negative 
clinical finding, and remains often difficult to manage in 
routine clinical setting. In another study, the skin irritation 
potential of a single application of FEN TDS and BUP TDS 
patches was compared in healthy volunteers.87 46 healthy Journal of Pain Research 2009:2 131
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males and females (mean age [range]: 59.6 [50 to 69] years) 
with healthy skin received a single dose of both the FEN 
TDS 25 µg/h patch and the BUP TDS 35 µg/h patch in a 
randomized order. The incidence and severity of erythema 
were assessed at various timepoints after patch removal. 
The results indicate that there was a non-significant trend 
towards a higher incidence of erythema 60 minutes after 
patch removal with BUP TDS compared with FEN TDS. 
The severity of erythema at 60 minutes and the incidence of 
erythema at 72 hours after patch removal were significantly 
higher with BUP TDS than with FEN TDS (P = 0.01 and 
22% vs 4.9%, P = 0.04, respectively). In general, the results 
from the chromametric assessment of treated skin were in 
agreement. The incidence of topical AEs was lower with 
FEN TDS than with BUP TDS (1 vs 6 events) and subjects 
preferred the fentanyl patch and felt it was less noticeable 
on the skin. The FEN TDS was considered less painful to 
remove, and, consistent with this, the BUP TDS patch was 
judged to have better adhesion.
Recently, the pharmacokinetics, analgesic efficacy, and 
irritancy potential of a new transdermal delivery system of 
buprenorphine (Buprederm®) were evaluated in rodents.88 
Interestingly, no skin irritation was demonstrated in rabbits 
after repeated Buprederm application. This new transdermal 
delivery system holds great promise to reduce the occurrence 
of skin irritation, but further clinical studies will need to prove 
its real-life value. In the mean time, several measures can 
be taken to prevent the occurrence of such skin irritation or 
at least reduce its severity. Preemptive treatment of the skin 
with a transparent by permeable film or topical application 
of a corticosteroid aerosol can effectively reduce the occur-
rence and intensity of skin reactions.
Future perspectives: expansion  
into new applications
In recent years, with expanding use of the transdermal 
buprenorphine patches, new challenging areas of clinical 
application have been identified. One of the most promis-
ing applications is the use of the BUP TDS in an intensive 
care setting. Many of these critically ill patients suffer 
from prolonged severe pain conditions (eg, post-traumatic 
pain, critical illness neuropathy, visceral pain syndromes), 
requiring sedation and intravenous administration of 
(high doses) of opioids for longer periods of time. This 
application is often complicated by (rapid) development of 
opioid-induced hyperalgesia whereby opioid administration 
results in a lowering of pain threshold, clinically manifest 
as apparent opioid tolerance, worsening pain, and abnormal 
pain sensations such as allodynia (for review see).89,90 Once 
opioid-induced hyperalgesia is diagnosed or provisionally 
considered, treatment strategies could include opioid dose 
reduction, use of agents with NMDA receptor antagonism, 
but also opioid rotation. The very specific (multimodal) 
pharmacological features of buprenorphine render this 
drug especially interesting for use in this vulnerable patient 
population. Experience in our center has indicated that 
treatment with BUP TDS is very useful and well tolerated 
in criticially ill patients.
Additionally, BUP TDS should be more often considered 
as a first-line therapeutic option in post-traumatic patients 
at the start of their (long-term) revalidation. In these cases 
treatment with buprenorphine patches could be initiated 
immediately post-operatively, providing the transition 
from more invasive analgesic treatments (eg, neuraxial 
or peripheral nerve blocks, PCA pumps) to continuous 
systemic analgesic therapy. Such treatment with BUP TDS 
can easily be tailored to the healing process of the patients, 
with decreasing doses as the patient recovers from the 
sustained injuries.
Conclusions
The pharmacological and clinical profiles of buprenorphine 
have been documented in a growing number of clinical 
studies, demonstrating buprenorphine’s potential effec-
tiveness in the treatment of diverse acute and chronic pain 
conditions. Buprenorphine shows no relevant analgesic 
ceiling effect throughout the therapeutic dose range, but 
indeed has a ceiling effect for respiratory depression. Most 
notably, buprenorphine seems to be potentially effective in 
the management of nociceptive pain syndromes as well as 
neuropathic hyperalgesic states and syndromes characterized 
by the presence of pronounced central sensitization. In addi-
tion, there seems to be no development of tolerance during 
long-term treatment. Finally, transdermal buprenorphine 
can be safely used in vulnerable patient populations, such 
as elderly and patients with renal impairment.
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